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ADVERSE IMPACT OF PREDISPOSITION TESTING ON MAJOR
LIFE ACTIVITIES: LESSONS FROM BRCA1/2 TESTING
KATHERINE A. SCHNEIDER, M.P.H.*
INTRODUCTION
Genetic testing for adult onset conditions is coming of age.
There are currently several dominant hereditary syndromes for which
testing can be performed prior to the onset of any signs of disease.
The availability of predisposition genetic testing brings great hope re-
garding treatment of genetic diseases yet may also be creating a new
genetic underclass of people, referred to by Paul Billings as "the
asymptomatic ill."1 Individuals who carry an inherited predisposition
to a specific disease are not ill or disabled by standard definitions, yet
they (and others around them) may perceive that their health status
has been dramatically altered.
There have been concerns that knowing one carries an inherited
predisposition to disease might adversely affect major life activities.
Major life activities include day-to-day functioning such as caring for
oneself, walking, talking, and breathing2 but might also be expanded
to include expected milestones such as getting married and having
children, setting and achieving professional goals, and becoming fi-
nancially secure. While the average person takes such milestones for
granted, individuals with chronic illness or disabilities face significant
obstacles along the way, including physical or psychological limita-
tions and negative societal perceptions. An individual at increased
risk for developing a future disease, based on a genetic test result, may
face similar types of obstacles despite his/her current level of health.
As Andrew Baum writes in his article on the stress of genetic testing,
"[u]ncertainty about one's future can affect long-term planning, re-
* Senior Genetic Counselor, Population Sciences, Department of Adult Oncology,
Dana-Farber Cancer Institute, Boston, Massachusetts; BA, Human Development, University
of California at Riverside, 1981; M.P.H., Yale University School of Public Health, 1985.
1. Rising Cost of Private Health Insurance, 1991: Hearing Before the Subcomm. on Commerce,
Consumer Protection, and Competitiveness of the House Comm. on Energy and Commerce, 102d
Cong. 12 (1991) (statement of Paul Billings, Vice Chairman, Dept. of Medicine, Pacific
Presbyterian Medical Center).
2. See 29 C.F.R. § 1630.2(i) (1999).
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productive decisions, health behaviors, and choices and expectations
for career, family, and the future."3
In this Article, the author explores the potential adverse impact
of predisposition testing on major life activities by using the example
of BRCA1/2 testing for breast cancer susceptibility. After providing a
brief overview of BRCA1/2 gene testing in Part I,' the author discusses
the potential short-term and long-term adverse effects of learning
one's BRCA1/2 gene status on emotional well-being in Part II. In
Part III, the author discusses the adverse effects of testing on personal
and familial relationships,6 while in Part IV, the author discusses the
negative impact of gene testing on insurability and employment
opportunities.7
I. BACKGROUND INFORMATION ABOUT BRCA1/2 TESTING
This section provides a description of the BRCA1/2 genes, associ-
ated cancer risks, and details about the testing process.
A. Inheritance Pattern of the BRCA1/2 Genes and Associated
Cancer Risks
Approximately 5%-10% of breast cancer cases are due to an in-
herited factor, i.e. a germline mutation in a breast cancer susceptibil-
ity gene.' The identification of two such genes, termed BRCA1 and
BRCA2, was completed approximately five years ago.9 Germline muta-
tions in the BRCA1 and BRCA2 genes account for most, but not all,
families with Hereditary Breast and Ovarian Cancer Syndrome
(HBOCS). ° DNA errors have been found throughout the BRCA1/2
genes, although three specific mutations seem to account for 90% of
3. Andrew Baum & Andrea L. Friedman, Stress and Genetic Testing for Disease Risk, 16
HEALTH PSYCHOL. 8, 9 (1997); see also THOMAS D. GELEHRTER ET AL., PRINCIPLES OF MEDICAL
GENETICS 265 (2d ed. 1998).
4. See infra text accompanying notes 8-22.
5. See infra text accompanying notes 23-52.
6. See infra text accompanying notes 53-60.
7. See infra text accompanying notes 61-82.
8. See KENNETH OFFIT, CLINICAL CANCER GENETICS: RISK COUNSELING AND MANAGE-
MENT 72 (1998).
9. See Yoshio Miki et al., A Strong Candidate for the Breast and Ovarian Cancer Susceptibility
Gene BRCA1, 266 SCIENCE 66, 66 (1994); Richard Wooster et al., Identification of the Breast
Cancer Susceptibility Gene BRCA2, 378 NATURE 789, 789 (1995).
10. See OFFIT, supra note 8, at 66-155.
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inherited breast cancers among individuals of Ashkenazi (Eastern Eu-
ropean) Jewish ancestry.'
Hereditary Breast and Ovarian Cancer Syndrome follows an auto-
somal dominant pattern of inheritance. 12 Both men and women can
carry BRCA1/2 mutations and can pass them on to their offspring."3
Each child has a 50% chance of inheriting the BRCA1/2 mutation. 4
Lifetime cancer risks for people with BRCA1/2 mutations are still
being established. Women have high lifetime risks of breast cancer
(approximately 50-85%) and increased risks of. ovarian cancer (ap-
proximately 2040% if BRCA-positive and 10-20% if BRCA2-posi-
tive).' 5 Women may also have slightly increased risks of other types of
cancer. 6 Men may have small, increased risks of specific cancers as
well, notably, breast and pancreatic cancer in BRCA2 mutation carri-
ers, but their daughters bear the most significant cancer risks.' 7 It is
important to emphasize that most men and some women with BRCA1/
2 mutations never develop cancer.'
B. Testing Options for BRCAJ/2 Mutations
BRCA1/2 testing is available in both clinical and research testing
programs. Individuals undergoing testing are recommended to re-
ceive genetic counseling both prior to testing and at results disclosure.
The genetic testing process begins by analyzing the entire BRCA1 and
BRCA2 genes in one family member, ideally someone likely to have a
mutation."' This means that the initial test is usually performed on a
11. See generally Dvorah Abeliovich et al., The Founder Mutations 185delAG and 5382insC
in BRCAI and 6174delT in BRCA2 Appear in 60% of Ovarian Cancer and 30% of Early-Onset
Breast Cancer Patients Among Ashkenazi Women, 60 AM. J. HUM. GENETICS 505, 505 (1997).
12. See GELEHRTER ET AL., supra note 3, at 265.
13. See Deborah Ford et al., Risks of Cancer in BRCA1-Mutation Carers, 343 LANCET 692,
694 (1994).
14. See Henry T. Lynch et al., DNA Screening for Breast/Ovarian Cancer Susceptibility Based
on Linked Markers, 153 ARCHIVEs INTERNAL MED. 1979, 1979 (1993).
15. See Douglas F. Easton et al., Breast and Ovarian Cancer Incidence in BRCA1-Mutation
Carriers, 56 AM.J. HuM. GENETICS 265, 270 (1995); The Breast Cancer Linkage Consortium,
Cancer Risks in BRCA2 Mutation Carriers, 91 J. NAT'L. CANCER INST. 1310, 1314 (1999); Jef-
fery P. Struewing et al., The Risk of Cancer Associated with Specific Mutations of BRCA1 and
BRCA2 Among Ashkenazi Jews, 336 NEw ENG. J. MED. 1401, 1401 (1997).
16. See Abeliovich et al., supra note 11, at 513.
17. See Noralane M. Lindor et al., The Concise Handbook of Family Cancer Syndromes, 90J.
NAT'L CANCER INST. 1039, 1048 (1998).
18. See id. at 1047-48.
19. See Katherine Schneider, Genetic Counseling for BRCAI/BRCA2 Testing, 1 GENETIC
TESTING 92 (1997).
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woman who has had ovarian and/or pre-menopausal breast cancer.
Finding a specific BRCA1/2 mutation in this woman positively estab-
lishes a link between the breast/ovarian cancer in the family and the
underlying genetic cause. It is then possible to offer site-specific ge-
netic testing to other blood relatives, including those who have not
had cancer.
To illustrate this point further, consider the example of two sis-
ters who are eager to have BRCA1/2 testing because their mother died
from breast cancer at age thirty-five and their maternal aunt was just
diagnosed with ovarian cancer. Genetic testing for this family would
ideally begin with the aunt to establish a link between the cancer and
a specific BRCA1/2 gene mutation. If the aunt does have a specific
mutation, then either or both sisters can decide to be tested for the
familial mutation. The tests for the sisters would be considered defini-
tive, i.e. either the mutation is present (a positive result) or absent (a
true negative result). However, if the aunt refuses to have BRCA1/2
testing, either or both sisters can still opt to be tested, but they would
need to undergo a full analysis of both genes. Furthermore, they
would be cautioned that a negative result in this scenario (termed in-
determinate negative) would not rule out the possibility of an inher-
ited susceptibility, although a positive result would continue to be
meaningful.
C. Uptake of BRCA1/2 Testing
Despite widespread availability of BRCA1/2 testing and high antic-
ipated uptake based on attitudinal surveys, only about half of the indi-
viduals eligible for testing elect to learn their gene status.21 People
decide not to have BRCA1/2 testing for a multitude of reasons. These
include a lack of interest in obtaining genetic information, uncer-
tainty that results would change their screening practices in any way,
fear that results could be positive, concerns about possible insurance
discrimination, and inappropriate timing because of seriously ill fam-
ily members or other stresses.2 2
20. KATHERINE A. SCHNEIDER, COUNSELING ABOUT CANCER: STRATEGIES FOR GENETIC
COUNSELORS 122-23 (1994) [hereinafter COUNSELING ABOUT CANCER].
21. See Caryn Lerman et al., BRCA1 Testing in Families with Hereditary Breast-Ovarian Can-
cer: A Prospective Study of Patient Decision Making and Outcomes, 275 JAMA 1885, 1890 (1996).
22. See Katherine Schneider et al., Testing for Cancer Genes: Decisions, Decisions, 1 NATURE
MED. 302, 303 (1995).
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II. ADVERSE EFFECTs ON EMOTIONAL WELL-BEING
At the extreme end of the spectrum, adverse emotional states,
such as anxiety, distress, or depression, can lead to feelings of hope-
lessness and suicidal ideation. However, even moderate levels of
these emotions can, over time, hamper one's ability to function on a
daily basis or impede personal or professional happiness.
In a thoughtful discourse on genetic testing, Andrew Baum
writes, "[a]s has often been the case, society's technological capabili-
ties have outpaced its understanding of the psychological conse-
quences."24  Although BRCA1/2 testing programs have been
reassuring about the lack of serious adverse psychological effects,25
many individuals do experience some degree of psychological distress
following the disclosure of their genetic test results.
Part II of this Article discusses the impact of genetic testing on
the emotional well-being of patients. The author discusses the base-
line emotional vulnerability of patients before testing and patients'
anticipated reactions to test results. Also described are the actual re-
actions to test results and the short-term and long-term impact of
learning results, including distress, depression, guilt, disease monitor-
ing behaviors, lowered self-esteem, goals and expectations, as well as
the effects of a negative test result.
A. Emotional Vulnerability at Baseline
Baseline levels of heightened anxiety and cancer-related distress
have been observed in both high risk clinics and genetic testing pro-
grams. One program reported that 13% of their high risk patients
had symptomatology consistent with an affective disorder,26 and in
our own BRCA1 testing program, we found 21.7% who, at baseline,
met criteria for needing further psychological assessment.2 7 The in-
creased anxiety and cancer-related distress can be due to a variety of
causes, but the most significant variable appears to be the person's
prior experiences with cancer in close relatives.28
23. See Baum & Friedman, supra note 3, at 8-9.
24. Id. at 9.
25. See Lynch et al., supra note 14, at 1983 (noting that, to date, there is no evidence
that disclosure leads to serious emotional disturbances).
26. See Penelope Hopwood et al., Psychological Support Needs for Women at High Genetic
Risk of Breast Cancer: Some Preliminaly Indicators, 7 PSYCHO-ONCOLoGy 402, 405 (1998).
27. See Stephanie A. Kieffer et al., Assessment and Management of Psychologically Challeng-
ing Cases in Predisposition Testing for Cancer Susceptibility, abstract presented at the National
Society of Genetic Counselors 15th Annual Education Conference (Oct. 26, 1996).
28. See Ora Gilbar, Women with High Risk for Breast Cancer: Psychological Symptoms, 80
PSYCHOL. REP. 800, 801 (1997).
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It is not uncommon for cancer risk counselors to refer patients to
a mental health professional for more in-depth counseling. Reasons
for making a psychological referral include the following: clinical
levels of depression, guilt, or anxiety; unresolved grief; suicidal idea-
tion; obsessive, intrusive thoughts about cancer or loss; overzealous
health vigilance; severe sleep or eating disturbance; disruptions in sex-
ual function and satisfaction; and relationship problems.
29
In a study of 256 women with at least one first-degree relative with
breast or ovarian cancer, higher levels of general distress were ob-
served in three groups of women: women who were not partnered,
women who were less optimistic, and women who had exaggerated
perceptions of their cancer risks combined with feelings that they had
little control over whether breast cancer occurred.30
These observations suggest that at least some individuals present-
ing for BRCA1/2 testing will be psychologically vulnerable and that
there are a variety of factors influencing reactions to the test results.
B. Anticipated and Actual Reactions from Test Result
Because BRCA1/2 testing is still new, there has been great interest
in identifying possible adverse reactions to learning test results.
Among the factors that may influence the reactions to test results are
biologic proximity and emotional ties to affected relatives, beliefs and
fears about cancer, history of childhood loss, major life transitions,
outcomes of cancer diagnoses, and family communication styles."'
Studies have examined both anticipated and actual reactions upon
disclosure of BRCA1/2 results.
1. Anticipated Reactions
Lerman and colleagues surveyed 105 first-degree female relatives
of breast cancer patients for interest in BRCA1 testing and anticipated
29. See generally Hopwood et al., supra note 26, at 404 (describing psychiatric problems
of subjects who participated in study); June A. Peters & Jill E. Stopfer, Role of the Genetic
Counselor in Familial Cancer, 10 ONCOLOGY 159, 160 (1996) (indicating several areas in
which genetic counselors incorporate active counseling); Jeffrey R. Botkin et al., A Model
Protocol for Evaluating the Behavioral and Psychological Effects of BRCA1 Testing, 88 J. NAT'L
CANCER INST. 872 (1996) (describing a model testing program which includes a psychologi-
cal assessment and plan for providing mental health referrals).
30. SeeJanet Audrain et al., Psychological Distress in Women Seeking Genetic Counseling for
Breast-Ovarian Cancer Risk: The Contributions of Personality and Appraisal, 19 ANNALS BEHAV.
MED. 370, 372-75 (1997).
31. See Peters & Stopfer, supra note 29, at 163.
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reactions to test results.3 2 Not surprisingly, most women expected to
have some degree of psychological sequelae3" from a positive test re-
sult, including increased anxiety (83%), depression (80%), and im-
paired quality of life (46%)." Interestingly, 72% of the women
thought that they would still worry about their cancer risks even if
their results were negative.3" Another study reported that women who
anticipated heightened anxiety with a positive test result were signifi-
cantly more anxious and depressed at baseline than the others
surveyed.3 6
2. Actual Reactions
Lynch and colleagues provided genetic counseling and testing to
388 individuals within 14 families with HBOCS.3 7 Of the 78 individu-
als who learned they had positive results, the initial reactions included
sadness (36%), anger (6%), and guilt (8%).3' Nineteen percent had
no apparent reaction, which could, at least in some, be indicative of a
shock response. 39 This is borne out by findings in a separate study,
which showed that individuals who exhibited lower anxiety and de-
pression scores at results disclosure seemed less willing or able to dis-
cuss the implications of the test results at that moment. 40
C. Short and Long Term Impact on Emotional Well-Being
Genetic testing research programs have observed and reported
several specific psychological responses to learning BRCA1/2 results,
including distress, depression, guilt, a negative impact on monitoring
behaviors, lowered self-esteem, goals, and expectations, and the ad-
verse effect of a negative test result.
32. See Caryn Lerman et al., Interest in Genetic Testing Among First-Degree Relatives of Breast
Cancer Patients, 57 AM. J. MED. GENETICS 385, 388 (1995).
33. "Sequela" is defined as a morbid condition following or occurring as a conse-
quence of another condition or event. See MILLER-KEANE ENCYCLOPEDIA & DICTIONARY OF
MEDICINE, NURSING, AND ALLIED HEALTH 1354 (Michael J. Brown, ed., 5th ed. 1992).
34. See Lerman, supra note 32, at 388.
35. See id.
36. See C. Julian-Reynier et al., Attitudes Towards Cancer Predictive Testing and Transmis-
sion of Information to the Family, 33 J. MED. GENETICS 731, 733 (1996).
37. See Henry T. Lynch et al., A Descriptive Study of BRCA1 Testing and Reactions to Disclo-
sure of Test Results, 79 CANCER 2219, 2220 (1997).
38. See id. at 2223.
39. See id.
40. See A. Christine Dudok deWit et al., Distress in Individuals Facing Predictive DNA Test-
ingfor Autosomal Dominant Late-Onset Disorders: Comparing Questionnaire Results with In-Depth
Interviews, 75 AM. J. MED. GENETICS 62, 71 (1998).
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1. Distress
Croyle and colleagues found that the twenty-five BRCA1 gene mu-
tation carriers in his series demonstrated higher levels of test-related
psychological distress when compared to the thirty-five noncarriers.
4
'
The highest levels of overall distress were in women who have never
had cancer and who had never undergone prophylactic surgery.
4 2
Another study found that levels of "cancer-specific" distress (i.e. dis-
tress specifically related to fears about developing cancer) were more
likely to be influenced by BRCA1 testing than overall or "global" levels
of distress.4" It is reassuring to note that the levels of distress associ-
ated with receiving positive BRCA1/2 results appear to significantly de-
cline by six months as people become adjusted to the information."
2. Depression
One BRCA1 testing program of 279 individuals did not find any
increased depression and functional impairment among the 53 with
positive results, although individual scores over time were not re-
ported.4 5 It is encouraging that BRCA1/2 testing does not appear to
cause major psychological sequelae, yet all testing programs have
clinical experiences that remind us of the power of this information.
Anecdotally, one woman tested through our program, who had not
anticipated a positive result, later admitted she could not recall any of
our lengthy discussion nor even who was present in the room during
the disclosure. She said that it took weeks before she could focus on
anything else. Another woman, whose husband and daughter both
carry BRCA1 mutations, related in a follow-up conversation that she
and her daughter were tearful for months afterwards as they struggled
to come to terms with the information.
3. Guilt
One of the most emotionally charged aspects about carrying an
inherited predisposition to breast cancer is that one's children or sib-
lings might have the disposition as well. Women who accept with
41. See Robert T. Croyle et al., Psychological Responses to BRCA1 Mutation Testing: Prelimi-
nary Findings, 16 HEALTH PSYCHOL. 63, 67 (1997).
42. See id at 69.
43. See Caryn Lerman et al., The Influence of Psychological Distress on Use of Genetic Testing
for Cancer Risk, 65 J. CONSULTING AND CLINICAL PSYCHOL. 414, 417 (1997).
44. See A.Chrsitine Dudok deWit et al., Course of Distress Experienced by Persons at Risk for
an Autosomal Dominant Inheritable Disorder Participating in a Predictive Testing Program: An Ex-
plorative Study, 60 PsYcHosoMATiC MED. 543, 545 (1998).
45. See Lerman et al., supra note 21, at 1885.
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equanimity the risks to themselves may find the same risks untenable
in their daughters. The initial person in the family who tests positive
may also feel guilty about "opening Pandora's box" within the family
and having to inform other members of the family that they are also at
risk. Conversely, family members who test negative for a familial mu-
tation may also experience guilt, termed survivor guilt,4 6 because they
were spared from the inherited cancer predisposition while others in
the family were not.
4. Negative Impact on Monitoring Behaviors
Nancy Wexler writes, "[w] ith a positive test, the ambiguity of wait-
ing for the disease may be unbearable. Gene carriers prematurely be-
come 'patients,' possibly forfeiting years of otherwise good health."4 7
Ms. Wexler is referring to individuals at risk for Huntington's Disease
(HD), but this statement also applies to women with a positive
BRCA1/2 test result. A positive result may exacerbate a woman's feel-
ings of vulnerability about developing cancer. In extreme cases, this
could either lead to a preoccupation with disease-related signs or to a
complete avoidance of physicians. Anecdotally, women with BRCA1/2
mutations identified through our program have indicated that their
routine cancer screening appointments are now more anxiety-provok-
ing. This is concerning, because in a study of 180 women, higher
levels of breast cancer worry were associated with poorer adherence to
mammography screening."
5. Lowered Self-Esteem
Upon being told of her positive BRCA1/2 result, one woman in
our testing program remarked that the result made her feel like "dam-
aged goods." Self-esteem is influenced by multiple factors, including
past experiences, personality type, coping mechanisms, support net-
work,4 9 and perhaps, in the future, by one's genetic make-up. Words
can invoke powerful images and considering the manner in which sus-
ceptibility genes are described-examples include damaged, defec-
tive, bad, mutated-it is certainly conceivable that a positive result
46. "Survivor guilt" is a guilty feeling individuals may experience when contrasting
their own good health with relatives who have developed cancer. See COUNSEUNG ABOUT
CANCER, supra note 20, at 108.
47. Nancy S. Wexler, Disease Gene Identification: Ethical Considerations, Hosp. PRAC., Oct.
15, 1991, at 147.
48. See Caryn Lerman, Adherence and Psychological Adjustment Among Women at High Risk
for Breast Cancer, 28 BREAST CANCER RES. & TREATMENT 145, 148 (1993).
49. See DEBORAH Y. ANDERSON & CHRISTOPHER L. HAVES, GENDER, IDENTITY, AND SELF-
ESTEEM xiii-xiv, 58-59, 142-43 (1996).
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could cause or reinforce lowered self-esteem. This is an area that de-
serves greater attention as more individuals with inherited susceptibili-
ties to disease are identified.
6. Lowered Goals and Expectations
BRCA1/2 testing is available to at-risk individuals who are 18 years
old or older. Thus, individuals being tested may still be in college or
in the midst of making career choices. Researchers do not yet know
how genetic test results will affect these decisions, although Nancy
Wexler and others have raised concerns about the impact of a positive
genetic test result, "[w]ill a young person, age 21, now aware that
there is a 95% probability of carrying the gene, expend the time,
money, and energy to achieve a chosen career?"
50
7. Adverse Effects of a Negative Test Result
A subset of patients who receive negative results will also experi-
ence adverse psychological sequelae. Contrary to expectations, nega-
tive results may not always relieve the individual's level of distress or
significantly improve his or her quality of life. In addition to exper-
iencing intense survivor guilt,5 1 individuals receiving so-called "good
news" may have difficulty assimilating the information after consider-
ing themselves at high risk for so long or may regret major life deci-
sions (such as choice of partner or career) that were influenced by
their fears of developing cancer. 52
III. ADVERSE EFFECTS ON PERSONAL AND FAMILIAL RELATIONSHIPS
June Peters and Jill Stopfer, both cancer genetic counselors,
write, "[t] he emotional impact of cancer goes beyond the person diag-
nosed with the malignancy; family and friends also are deeply af-
fected."5 3 This statement is equally apropos for individuals found to
have an inherited predisposition to cancer. In this section, the author
discusses the impact of testing on family relationships as well as deci-
sions about marriage and child-bearing.
50. Wexler, supra note 47, at 147.
51. See supra note 46.
52. See COUNSEUNG ABOUT CANCER, supra note 20, at 129-30 (discussing risks associated
with negative results regarding the carrying of altered genes).
53. Peters & Stopfer, supra note 29, at 163.
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A. Impact on Family Relationships
Relationships within a family can change dramatically as family
members share their test results with one another. Individuals may
have complicated reactions to learning a relative's result because it
has serious implications both for their relatives and for themselves.
Blood relatives, some of whom may have only vaguely been aware of
the cancer history, may suddenly be faced with being at increased risk
of cancer and having to make unwelcome decisions about testing. 4
At the Dana-Farber Cancer Institute genetic testing program, we
have witnessed serious family rifts develop as a consequence of genetic
testing. This has occurred, for example, when the only living affected
family member either declines to be tested to the great disappoint-
ment of at-risk relatives or feels as though he or she is being coerced
into testing by relatives. Testing may also cause family members to
share and discuss information that had never been talked about. In
one of the families with whom I worked, the mother had concealed
her extensive personal and familial history of cancer from her five
adult children until she received a positive genetic test result; disclo-
sure of this information caused a severe family rift. Family conflicts
may also arise as family members make different decisions about be-
ing tested or about their medical management post-disclosure. 5
Learning one's test results can also cause a certain awkwardness
when talking to other family members or friends. As examples, one
testing participant in her twenties stated that she had no one to talk to
about her positive BRCA1/2 result; her husband and family members
became upset whenever she mentioned it, and her friends, who never
worried about cancer themselves, had difficulty relating to her situa-
tion. Another woman, with a negative result, spoke of feeling "left
out" when her sister and female cousin spoke of issues relating to
their positive results.
B. Impact on Marriage and Child-Bearing Decisions
The effect of genetic testing on marital and childbearing prac-
tices is not yet known. In a survey of 105 women, about one fourth
thought that learning their BRCA1 results would be important in mak-
ing marital decisions and about one half thought it would be impor-
tant in making childbearing decisions.56
54. See COUNSELING ABOUT CANCER, supra note 20, at 125-26.
55. See id. at 121-39.
56. See Lerman et al., supra note 32, at 388.
375
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1. Decisions about Marriage
As stated earlier, women with higher levels of general distress
were more likely to be unmarried.57 It is not yet known whether wo-
men who test BRCA1/2 positive will be less likely to seek marriage af-
ter learning their results or whether they could face greater difficulty
finding partners. The latter may be especially problematic for women
in cultures where marriages are frequently arranged and may cause
these women to decline testing for fear of stigmatization.5"
2. Child-Bearing Decisions
Women with positive BRCA1/2 results are offered the option of
prophylactic oophorectomy (surgical removal of ovaries) to reduce
their risks of ovarian cancer. 9 Thus, women may decide to have their
children at younger ages rather than delaying childbearing until their
late thirties or early forties. Some women may elect to have fewer chil-
dren or not to have children at all, either because of fears that they
might pass on the gene mutation to their offspring or fears that they
might not live long enough to raise a child to adulthood.'
IV. ADVERSE EFFECTS ON INSURANCE AND EMPLOYMENT
A. Genetic Discrimination
In an article discussing the potential ramifications of genetic test-
ing, Marvin Natowicz warns, "[tihe practice of genetic discrimination
has the potential of creating a new group of disadvantaged people
who will need the same protections now accorded those suffering
from race and sex discrimination."61 Genetic discrimination is de-
fined as:
discrimination against an individual or against members of
that individual's family solely because of real or perceived
differences from the "normal" genome in the genetic consti-
tution of that individual ....
People at risk for genetic discrimination are (1) those
individuals who are asymptomatic but carry a gene(s) that
57. See Audrain et al., supra note 30, at 372.
58. See Renee Royak-Schaler & Beryl Lieff Benderly, The Role of Risk in Daily Life, in
CHALLENGING THE BRiAsr CANCER LEGACY 132 (1992).
59. See Lerman et al., supra note 21, at 1891.
60. See COUNSELING ABOUT CANCER, supra note 20, at 110.
61. Marvin R. Natowicz et al., Genetic Discrimination and the Law, 50 AM. J. HUM. GENET-
ics 465, 465 (1992).
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increases the probability that they will develop some disease,
(2) individuals who are heterozygotes (carriers) for some re-
cessive or X-linked genetic condition but who are and will
remain asymptomatic, (3) individuals who have one or more
genetic polymorphisms that are not known to cause any
medical condition, and (4) immediate relatives of individu-
als with known or presumed genetic conditions.62
1. Extent of Genetic Discrimination
To date, there have been few reported cases of genetic discrimi-
nation among individuals with BRCA1/2 mutations, although until re-
cently, most testing occurred within protected research programs.
With the advent of commercial testing has come increased physician
referrals for genetic testing (which may be duly noted in medical
charts) and increased requests for reimbursement of testing-related
expenses.63 Thus, it will be important to continue monitoring this
issue over time. There have been several well-documented cases of
genetic discrimination experienced by individuals with a variety of ge-
netic disorders, including one case of a woman with a family history of
Huntington's Disease, who was told that she would qualify for a life
insurance policy only if she underwent genetic testing and was found
to be negative.64
2. Patients' Perception of Genetic Discrimination
Individuals considering BRCA1/2 testing consistently identify
health insurance discrimination among their major concerns about
testing. In one testing program, 34% of individuals reported that the
possibility of losing health insurance was a major risk of having BRCA1
testing.65 This fear may discourage individuals from being tested and
may also keep individuals from sharing positive test results-poten-
tially important medical information-with their physicians.
B. Insurance Discrimination
Genetic discrimination by insurers may result in canceled or de-
nied health, life, or disability insurance policies, limitations in cover-
62. Id. at 466.
63. See generally The Ad Hoc Committee on Genetic Testing/Insurance Issues, Back-
ground Statement: Genetic Testing and Insurance, 56 Am. J. HuM. GENETICS 327, 328-29 (1995)
[hereinafter The Ad Hoc Committee on Genetic Testing/Insurance Issues] (discussing
implications of genetic testing with respect to insurance policies).
64. See Paul R. Billings et al., Discrimination as a Consequence of Genetic Testing, 50 AM. J.
HuM. GENETICS 476, 480 (1992).
65. See Lerman et al., supra note 21, at 1890.
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age, or higher premiums for coverage. At present, insurers do not
themselves conduct genetic testing for applicants, although they may
be interested in learning the test result.66 Insurers can gain access to
genetic test results through physician records or by asking the individ-
ual for the result during the application process. 67 Individuals are re-
quired to answer such questions honestly or they are at risk for policy
cancellation or legal prosecution for insurance fraud.6"
1. The Practice of Underwriting
Individual rates of insurance are determined by considering the
person's overall risk factors and chances of morbidity or untimely
death.69 Individuals with few risk factors pay average rates, while indi-
viduals with unique or multiple risk factors pay higher rates or are
denied policies altogether. 70 Thus, higher rates are charged to smok-
ers, diabetics, and motorcyclists. However, this practice becomes
more problematic when considering individuals who are asymptom-
atic yet carry inherited susceptibilities to disease. For individuals with
BRCA1/2 mutations, two central questions are raised: does a germline
BRCA1/2 mutation constitute a pre-existing condition?; and do insur-
ers have the right to base policy decisions on possible future disease?
a. Does a germline BRCA1/2 mutation constitute a pre-existing
condition ?
It is true that BRCA1/2 mutations, which are associated with
HBOCS, are present from birth. However, individuals with BRCA1/2
mutations are not born with any signs or symptoms of HBOCS and, in
fact, may not develop cancer for several decades (if at all) .7' Thus, it
does not seem appropriate to label a person as having a pre-existing
condition years before the onset of symptoms. The condition should
be considered present with the first signs of disease, not before. It is
also inappropriate to label a person as having a "pre-existing condi-
tion" because of his/her genetic make-up (as opposed to behavior
which is theoretically under the person's control), especially since all
66. See Gail Geller et al., Genetic Testing for Susceptibility to Adult-Onset Cancer: The Process
and Content of Informed Consent, 277JAMA 1467, 1471 (1997).
67. See id.
68. See id.
69. See The Ad Hoc Committee on Genetic Testing/Insurance Issues, supra note 63, at
327.
70. See generally id. (describing how standard premiums are calculated based upon the
provider's expected outcome for different groups of individuals with similar risks).
71. See generally Lynch et al., supra note 37, at 2223 (noting that there is a limited ability
to predict the age of cancer onset among BRCAl-positive individuals).
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human beings are thought to carry deleterious genes that predispose
to disease.
b. Do insurers have the right to base policy decisions on possible
future disease?
The entire premise of underwriting is based upon making predic-
tions about future disease given certain characteristics or behaviors. 72
The concern about basing decisions on genetic test results, such as a
positive BRCA1/2 result, is the inability to assign risks of disease or
eventual outcome (i.e. death) with any precision. This may change in
the future as our knowledge base grows, yet even with HD, a condition
with 100% penetrance, it is not possible to predict the age at which
symptoms will occur or how rapid the disease course will be.73
2. The Issue of Adverse Selection
An alternative problem, from the perspective of the insurer, is
adverse selection. Adverse selection occurs when individuals have
more information about their risks of specific illnesses than do their
insurance companies.7 ' Not only does this allow these "high risk" in-
dividuals to purchase insurance at the same rates as those designated
"average risk," but it might lead individuals to obtain more insurance
than they otherwise would have. Adverse selection has the potential
for jeopardizing the economic well-being of the insurance company
or may lead companies to raise all premiums as protection.75
C. Employment Discrimination
Genetic discrimination by employers refers to unfavorable treat-
ment in hiring, promotion, assignment of duties, and privileges of em-
ployment.76 There are concerns that individuals with positive BRCA1/
2 test results will be viewed as less desirable employees because of their
potential for serious illness. Since a number of cancer survivors as
well as individuals with genetic disorders have experienced workplace
discrimination, 77 these concerns would appear to be valid. The Amer-
72. See The Ad Hoc Committee on Genetic Testing/Insurance Issues, supra note 63, at
327.
73. See GELEHRTER ET AL., supra note 3, at 28, 217.
74. See The Ad Hoc Committee on Genetic Testing/Insurance Issues, supra note 63, at
329.
75. See id.
76. See Council on Ethical and Judicial Affairs, American Medical Association, Use of
Genetic Testing by Employers, 266 JAMA 1827, 1827 (1991).
77. See Billings et al., supra note 64, at 478; see also Mark A. Rothstein et al., Are Cancer
Patients Subject to Employment Discrimination?, 9 ONCOLOGY 1303, 1306 (1995).
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ican Medical Association Council on Ethical and Judicial Affairs has
carefully considered potential uses of genetic testing by employers.78
Their report discusses three major rationales that might be used to
justify genetic discrimination by employers: 1) public safety issues; 2)
employee safety issues; and 3) higher costs and lower productivity. 79
1. Public Safety Issues
There may be rare instances when the risk of illness or disability
in the employee can negatively impact public safety. This is unlikely
to be the case for employees with BRCA1/2 mutations; however, it
might be an issue for individuals at risk for other serious genetic con-
ditions. For example, should a commercial airline continue to em-
ploy a pilot who is at 50% risk for developing Huntington Disease's
(HD), a degenerative neurological condition? If this individual is
showing signs of HD, then it seems clear that concerns about public
safety should prevail, and the pilot should no longer be allowed to fly.
However, consider an individual at risk for HD, who may not develop
any symptoms of HD for ten, twenty, or even thirty years. Arguing
that this individual is a public safety hazard based on "possible future
illness" seems much less reasonable, especially since all commercial
pilots are required to demonstrate physical and neurologic fitness on
an annual basis. It would be difficult to prove that employees who
might in the future develop a specific illness or disability pose a risk to
public safety.
2. Employee Safety Issues
It is the employer's duty to protect employees from unnecessary
harm. Thus, there may be instances when an employer is justified in
basing employability or job assignments on an individual's genetic
make-up or risk of future health problems. However, several condi-
tions must be met before this is allowable: a) the individual's genetic
make-up must be known to make him/her unusually susceptible to
injury from chemicals or other substances in the workplace; b) health
problems in other employees working with these chemicals or sub-
stances occur rarely or never; and c) the cost of reducing the expo-
sure-related risks for the employee is prohibitive.8" Given these
stringent conditions, very few predictive genetic tests (if any) would
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qualify, and therefore, it is unlikely that employee safety issues will
prove to be valid justification for genetic discrimination.
3. Higher Costs and Lower Productivity
Employers, particularly in small businesses, may feel that it is pro-
hibitively expensive to cover health, life, or disability insurance poli-
cies for employees with inherited susceptibilities to disease.
Employees may also be less than enthusiastic about hiring individuals
who may not be able to work as long or as productively because of the
impending threat of illness or disability. However, since the Ameri-
cans with Disabilities Acte' states that disabled individuals have the
right to employment despite possible additional costs to the em-
ployer,8 2 this argument is certainly not valid for individuals who are
currently healthy but predisposed to future disease.
CONCLUSION
In the words of Michael Yesley, "[g] enetic information will play a
central role in health care, but it may destroy individuals' self-esteem
and be used to discriminate against them." 3 This one sentence cap-
tures both the promise and the peril of predisposition genetic testing.
The major challenges to health care providers and policy-makers are
to ensure that individuals have adequate pre- and post-test counseling,
access to appropriate medical resources, and protection from all
forms of genetic discrimination.
81. See 42 U.S.C. §§ 12101-12213 (1994).
82. See Council on Ethical and Judicial Affairs, supra note 76, at 1828.
83. Michael S. Yesley, Editor's Introduction to Eric T. Juengst, The Ethics of Prediction: Ge-
netic Risk and the Physician-Patient Relationship, 1 GENOME Sci. & TECH. 21 (1995).
